How can supply of penicillin be an issue in any country in 2013?

September 26, 2013

Benzathine penicillin G (BPG) is the most essential antibiotic for the treatment and prevention of group A streptococcal infections associated with rheumatic fever and rheumatic heart disease. Yet while some countries such as South Africa and Brazil have stable supplies, most countries with a high RHD burden often suffer interruptions in supply and also have quality control issues. The problems around supply of this drug are discussed in one of the papers of the RHD special issue of Global Heart, the journal of the World Heart Federation. The paper is by Dr Rosemary Wyber, Telethon Institute for Child Health Research, Centre for Child Health Research, The University of Western Australia, Perth, Australia and colleagues.

Secondary prophylaxis is used to prevent cases of rheumatic fever developing into full blown RHD, and requires monthly injections of BPG for at least 10 years, although for some severe cases lifelong prophylaxis is required. Delivering each injection in secondary prophylaxis regimes is a global challenge. In most setting fewer than eighty percent of scheduled injections are delivered (the only country that routinely achieves >80% is New Zealand). Most countries probably achieve only the minority of injections, significantly increasing the risk of (ARF).

The authors highlight that despite many of the world's being able to supply their populations with HIV medications for those infected, these same countries can struggle to supply BPG, a drug that has been around for decades. BPG is considered an essential medicine by the World Health Organization, yet erratic supply means it is often unavailable to the impoverished people relying on it to prevent the progression of RHD.

One of the issues possibly causing supplies of BPG to be intermittent is its dwindling potential to be used for other conditions such as syphilis, which now can be largely treated with other drugs. The authors add: "As has receded as a public health priority in most high-income settings, attention to the supply, manufacture, and accessibility of BPG has declined. Concerns about the quality, efficacy, and innovation of the drug have emerged following plasma analysis and anecdotal reports from low-resource settings."

Issues around actual administration of the drug include pain while injecting—in some programs local anaesthetic is routinely used as a diluent for BPG to reduce injection pain. Unexpectedly high rates of severe allergy and anaphylaxis have also made secondary prophylaxis programs difficult. Generally accepted international data suggests that the incidence of allergic reactions to monthly BPG injection is 3.2% and anaphylactic reactions is 0.2%. However, episodes of anaphylaxis in India have seen BPG injections outlawed in some states.

The authors say: "An implantable or longer acting BPG delivery device would be a more appropriate and acceptable mechanism for delivering secondary prophylaxis." They advocate ongoing research into novel delivery devices, partnerships with industry, market shaping interventions and procurement support to improve supply. Dr Wyber summarises "Making this essential medicine available to vulnerable populations is the most important step in reducing death and disability from RHD. Researchers, industry, governments and communities need to commit to delivering this low cost, life changing intervention".

The authors conclude: "Securing and delivering high-quality supplies of BPG is a surmountable challenge; powdered formulations are off-patent, fixed-dose, do not require a cold chain, and demand can be forecast in predictable volumes for many years. In comparison to the complexities of early antiretroviral regimes and vaccination efforts, universal access to BPG is eminently achievable...Global institutional leadership will be required to move forward on priority issues for improving access."

Explore further: Screening programs detect cases of undiagnosed rheumatic heart disease in low-resource countries

Related Stories

Screening programs detect cases of undiagnosed rheumatic heart disease in low-resource countries

April 21, 2012
Widespread screening of children in poorer countries is now being studied and is resulting in the diagnosis of rheumatic heart disease (RHD) in patients that would likely have gone undetected under normal circumstances, according ...

Roadmap to 25 percent reduction in premature deaths From RHD in the under 25s by 2025 published

April 8, 2013
The World Heart Federation has published a new position statement outlining the five key strategic targets required to meet its strategic goal for rheumatic heart disease (RHD) – a 25% reduction in premature deaths from ...

Rheumatic heart disease treatment is too late to prevent heart surgery in the Middle East

April 19, 2012
Patients with rheumatic heart disease (RHD) are being admitted to hospital too late to prevent the need for heart surgery, according to a new study carried out by doctors in Yemen and presented today at the World Congress ...

First international guidelines for echocardiographic diagnosis of rheumatic heart disease

February 28, 2012
The inaugural international guidelines for the diagnosis of rheumatic heart disease (RHD), a disease that affects tens of millions of people worldwide, have today been published by the World Heart Federation in Nature Reviews ...

Scientists discover new type of protein modification, may play role in cancer and diabetes

August 1, 2013
Scientists at The Scripps Research Institute (TSRI) have discovered a new type of chemical modification that affects numerous proteins within mammalian cells. The modification appears to work as a regulator of important cellular ...

New approaches to combating rheumatic fever in children

February 5, 2013
Leading international researchers and doctors are meeting at the University of Otago, Wellington this week to identify new approaches to reducing the very high levels of rheumatic fever in New Zealand and Australia.

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.